Class / Patent application number | Description | Number of patent applications / Date published |
424485000 | Natural gums, resin or latex | 21 |
20080220064 | EXTENDED RELEASE MATRIX FORMULATIONS OF MORPHINE - The present invention provides extended-release matrix formulations comprising a therapeutically effective amount of morphine or salt thereof, one or more hydrophilic controlled release polymers and one or more pharmaceutically acceptable excipients. The formulations provide extended release of morphine or salt thereof over a specified period of time after oral administration in humans or animals. | 09-11-2008 |
20090011024 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers - A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment. | 01-08-2009 |
20090017120 | Phase stable lecithin organogel composition - A lecithin organogel composition used to deliver pharmaceutical products transdermally as well as a method for producing the lecithin organogel composition, which may contain up to 40% additive ingredients. Preferred embodiments of the invention may include lecithin organogel compositions which provide high penetrating power, which are ready-to-use, which have improved stability, which have a high uptake capacity for active drugs, and which do not grow mold if the gel becomes contaminated. | 01-15-2009 |
20090130213 | Rapidly disintegrating solid oral dosage form - Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, or less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity. | 05-21-2009 |
20100028434 | Temperature controlled and pH dependent self gelling biopolymeric aqueous solution - The present invention relates a biopolymeric liquid aqueous composition for producing self-gelling systems and gels, which comprises: an acidic water-based medium, 0.1 to 10% by weight of a pH-gelling acid-soluble biopolymer; and 0.1 to 10% by weight of a water-soluble molecule having a basic character and a pKa between 6.0 and 8.4, or a water-soluble residue or sequence of the molecule having a basic character and a pKa between 6.0 and 8.4. The liquid composition has a final pH ranging from 5.8 and 7.4, and forms a stable solid and homogeneous gel within a temperature range from 10 to 70° C. The present invention also relates to a method for preparing the composition and uses thereof. | 02-04-2010 |
20100074955 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity - The present invention relates to an active substance combination comprising at least one compound with 5-HT | 03-25-2010 |
20100151028 | CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed. | 06-17-2010 |
20100316718 | ACTIVATED FOAM - The present invention relates to an activated foam made of a natural or synthetic rubber or a synthetic resin, characterized in that the foam contains a zirconium compound and/or a germanium compound, and has a closed-cell structure, wherein the foam is used so as to directly or indirectly contact with a human body when a pharmaceutical agent is administered. The activated foam can be directly or indirectly contacted with a human body to facilitate blood circulation and promote the improvement of physical condition and the cure of diseases. It also has no adverse effect. | 12-16-2010 |
20110064810 | TISSUE ENGINEERING METHOD FOR ORGAN RECONSTRUCTION USING INJECTABLE MATRIX - The various embodiments herein relate to an injectable matrix used for regeneration, reconstruction, repair or replacement of organ or tissue. The injectable matrix consists of a synthetic and natural polymer, a stem cell niche and nanoparticles in the form of cups filled with growth factor and physiologic agent. The embodiments herein also provide a method for regeneration, reconstruction, repair or replacement of organ or tissue. In the method, an injectable matrix is injected to create three dimensional matrix system or network in an area of the desired tissue or organ, migration of blood circulatory stem cells or tissue-specific progenitor cells occur to the injected area of the tissue or organ. The growth factors and physiological agent present in the nanocups are released. The stem cells proliferate and differentiate to form the desired organ or tissue. | 03-17-2011 |
20110097405 | ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM - The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain estradiol, or derivatives thereof, in low amounts. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen. | 04-28-2011 |
20110117196 | Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects - The invention provides a novel solid pharmaceutical dosage form which includes an opiate, an opiate antagonist admixed with the analgetic (opiate agonist) and an amount of a hydrocolloid containing excipient which is effective to form a non-injectable slurry when the dosage form is contacted with water. In addition the dosage form contains pure naloxone in enteric coated form which is designed to release in the colon to prevent or relieve constipation. Thus the formulation, because of the enteric coated naloxone and the hydrocolloid excipient(s), has reduced side effects as compared with formulations which do not contain these features. | 05-19-2011 |
20110217378 | IMMOBILIZATION OF BIOACTIVE MOLECULES WITHIN A POLYMERIC SUBSTRATE - It is described a technology which allows to surpass the gastric barrier for proteic compounds administrating bioactive molecules, particularly insulin. It is proposed a method to replace the daily repetitive injectable doses of insulin by a product orally administered. It is characterized by the following steps: a) mix at least a monomer suitable for polymerization by means of a ionizing radiation, with at least an aqueous solution of bioactive molecules; place the thus obtained mixture in step (a) into a resistant container permeable to said ionizing radiations; submit said container to a flow of ionizing radiation at a dose capable to polymerize all the monomer, in a dose range from 0.1 kGy up to 50 kGy, particularly in a 5 to 30 kGy in range, obtaining within the container a polymer resistant to the stomach acids. And the polymer containing in its nanotubules bioactive molecules; withdraw the thus polymer obtained in step (c), and dividing it in batches with a size range of 1 mm×1 mm×1 mm up to 8 mm×8 mm×8 mm. It is an objective of this invention. A method for the introduction of bioactive molecules in a polymeric substrate resistant to the stomach acids, to be employed as a retarding orally administered medicine, being these molecules insulin which is release directly to the liver being the liver its first action site, through the portal circulation; an orally released insulin of delayed action by means of which, when the insulin is released into the liver, controls the production of hepatic glucose; an orally released insulin of delayed action by means of which the insulin does not produce peaks in the systemic circulation, as it does with the injectable insulin, reducing the risks of the sudden decrease in the glucemia levels, an orally administered medicine with a prolonged retared effect, by means of which it is necessary a lesser insulin dose. | 09-08-2011 |
20110244045 | CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION - The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof. | 10-06-2011 |
20110293720 | PROGESTIN-CONTAINING DRUG DELIVERY SYSTEM - The present invention relates to drug delivery compositions in the form of thin water-soluble films (wafers), which contain small particles that comprise at least one progestin and at least one protective agent. The protective agent provides effective taste-masking of the progestin due to limited release of the progestin in the mouth. The progestin is hence not absorbed via the buccal route, but rather via the enteral (per-oral) route. | 12-01-2011 |
20120114754 | RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM - Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity. | 05-10-2012 |
20120183618 | MODULAR SYSTEMS FOR THE CONTROLLED RELEASE OF A SUBSTANCE WITH SPACE AND TIME CONTROL - An innovative pharmaceutical form for controlled drug release relates to systems obtained by the assembly of individual release modules, of which the capacity to release the drug in time and in space depends on the way in which the modules have been assembled. The modular structure offers high reproducibility of manufacture and flexibility of release. | 07-19-2012 |
20120201891 | TRANSDERMAL DELIVERY PATCH - A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier. | 08-09-2012 |
20120207836 | DRUG DELIVERY SYSTEMS (WAFER) FOR PEDIATRIC USE - The present invention describes drug delivery compositions in the form of thin water-soluble films (wafers), which contain particles that comprise at least one active ingredient—which is not an estrogen and/or a progestin and/or an alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolate—and at least one protective agent. The protective agent provides effective taste-masking of the active ingredient due to limited release of the active ingredient in the mouth. The active ingredient is hence not absorbed via the buccal route, but rather via the enteral (per-oral) route. The particles contained in the wafer provided by the present invention have a particle size of below 40 μm thereby resulting in an acceptable sensation in the mouth while dissolving. Such wafers are especially suitable for pediatric use. | 08-16-2012 |
20120282340 | DRUG DELIVERY SYSTEM - The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain an Estrogen Receptor beta (ER-β) selective agonist. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen. | 11-08-2012 |
20120288566 | LIQUID PRECURSOR COMPOSITIONS AND USES THEREOF FOR A PH-DEPENDANT SUSTAINED RELEASE TREATMENT OF ORAL DISORDERS - The present invention discloses liquid precursor compositions adapted for application on a hard surface in the oral cavity, comprising at least one therapeutic agent suitable for the treatment of oral disorders, at least one acidic-pH sensitive polymer, at least one hydrophobic polymer, and a pharmaceutically acceptable volatile carrier, wherein a weight ratio between said at least one hydrophobic polymer and said at least one acidic-pH sensitive polymer is larger than 1. The invention also discloses formulations formed of the solidification of these compositions, and methods for treating oral disorders by applying these compositions on hard surfaces in the oral cavity or to be placed in the oral cavity. | 11-15-2012 |
20130171256 | ALCOHOL-RESISTANT EXTENDED RELEASE DOSAGE FORMS COMPRISING VENLAFAXINE - This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing venlafaxine or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance. | 07-04-2013 |